ERBB2 and breast cancer: Initially, we established the acquired lapatinib-resistant HER2 + breast cancer cell models SKBR3-L and BT474-L, characterized by sharply increased IC50 values (approximately 48 and 66-fold higher than those of their parent cells) in cell proliferation and colony formation assay following treatment with lapatinib (Figures 1A,C).